14 of 50 GLP‑1 telehealth programs have received an FDA warning letter

We track 50 online GLP-1 programs and re-read each of them every week.2 14 of them — 28.0% — are matched to an FDA warning letter addressed to the firm behind the program.1 The matches run from September 2025 to June 2026.

The FDA's GLP-1 warning letter register holds 157 letters, 110 of them addressed to online sellers.1 Only 13 attach to a program we list. The gap does not mean the rest were cleared. It is the difference between the whole direct-to-consumer market and the 50 programs we keep verified. The figure is a floor for the programs we cover, not a count of enforcement in the market.

A letter is attributed to a program only where the recipient firm can be identified as the company behind it with confidence.1 Programs trade under a consumer brand, contract compounding to a third party, and sometimes share a corporate parent with a firm under a different name. An unmatched letter stays in the warning letter register and is counted there, not here, so this number understates rather than overstates.

None of the matches carries a recorded resolution.1 The FDA publishes closeout letters for a minority of matters, and usually more than a year later, so an absent resolution is the normal state of a recent letter. What the letter establishes is that the agency published an allegation, on a date, against a named company.

Names link to the page for that record where one is published.

The first input is the FDA's published warning letters, filtered to those naming a GLP-1.1 The second is the programs listed here: the glp1.health Check re-reads each program's price, fees, states served, pharmacy and enforcement record every week.2 The figure is the count of listed programs with at least one matched letter, over the count of listed programs.

The denominator is the 50 programs we list and verify each week, not a census of everyone selling a GLP-1 online. Nobody publishes that census.

The sources list says which figures come from the Check and which from the FDA.

1. A warning letter is an allegation the FDA has published. It is not a court finding.
2. A letter is attributed to a program only where the named firm matches it with confidence. Unmatched letters are counted in the register, not here.
3. The denominator is the programs tracked on this site, not every GLP-1 seller in the United States.
4. Absence of a recorded resolution is common for recent letters and is not evidence of unresolved violations: the FDA publishes closeout letters for a minority of matters, typically more than a year later.